

PRODUCT INFORMATION

| | |
|---|--|
| Common Name | BG-9588, hu5c8 |
| Synonyms | CD40LG;CD154;CD40L;HIGM1;IGM;IMD3;T-BAM;TNFSF5;TRAP;gp39 |
| Applications | ELISA; Flow Cyt |
| Recommended Dilutions | ELISA 1:5000-10000; Flow Cyt 1:100 |
| Formulation & Reconstitution | Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution. |
| Host Species | Humanized |
| IgG type | IgG1 |
| Reactivity | Human |
| Target | CD40 Ligand |
| Uniprot ID | P29965 |
| Description | Anti-CD40L (ruplizumab biosimilar) mAb |
| Delivery | In Stock |
| Storage & Shipping | Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature. |
| Background | Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals. |
| Usage | Research use only |
| Conjugate | Unconjugated |
| DIMA Disclaimer | All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scrutinizing all patent application to ensure no IP infringement. |

Anti-CD40 Ligand (ruplizumab biosimilar) mAb ELISA

0.2 µg of Human CD40 Ligand, hFc Tagged protein per well




Figure 1. ELISA plate pre-coated by 2 $\mu\text{g/ml}$ (100 $\mu\text{L/well}$) Human CD40 Ligand Protein, hFc Tag (PME100192) can bind Anti-CD40 Ligand (ruplizumab biosimilar) mAb (BME100042) in a linear range of 0.64-400 ng/ml. In order to specifically detect BME100042, mouse anti-human Fab-specific antibody was used as detection antibody.




Figure 2. HEK293 cell line transfected with irrelevant protein (B) and human CD40L (A) were surface stained with Anti-CD40L mAb 1 $\mu\text{g/ml}$ (ruplizumab) followed by Alexa 488-conjugated anti-human IgG secondary antibody.

